Semaglutide Reduces Alzheimer's Brain Inflammation by Switching Microglia from Attack Mode to Repair Mode

Semaglutide (25 nmol/kg IP every 2 days for 30 days) promoted M1-to-M2 microglial transition in 3xTg Alzheimer's mice, reducing neuroinflammation, decreasing hippocampal amyloid-β deposits, and improving memory performance.

Seven-month-old 3xTg (APP/PS1/tau) and wild-type mice were divided into four groups: WT+PBS, 3xTg+PBS, WT+semaglutide, 3xTg+semaglutide. Semaglutide (25 nmol/kg) was injected intraperitoneally every 2 days for 30 days. Behavioral tests assessed memory; molecular analyses measured inflammatory markers, microglial polarization, and amyloid deposition. BV2 microglial cells were used for in vitro confirmation.

Semaglutide is already widely prescribed for diabetes and obesity. If it can also calm brain inflammation and slow Alzheimer's progression — as this animal study suggests — it could be repurposed for neurodegenerative disease, potentially helping millions of people.

This study adds to a growing body of evidence that GLP-1 receptor agonists like semaglutide have neuroprotective effects beyond metabolic benefits. Multiple clinical trials are now investigating these drugs for Alzheimer's and Parkinson's disease. The microglial polarization mechanism identified here provides a specific, testable pathway for how these drugs might protect the brain.

Mouse model — the 3xTg model doesn't perfectly replicate human Alzheimer's. Intraperitoneal dosing differs from human subcutaneous injection. 30-day treatment is short relative to human disease progression. Whether microglial M1/M2 polarization translates cleanly to human brain immune responses is debated.